Skip to main content
Log in

Why I No Longer Consult for Drug Companies

  • Opinion
  • Published:
Culture, Medicine and Psychiatry Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. To be disciplinarily fair, a few sociologists, particularly Drs. Jennifer Fishman and Susan Hinze of my home university also have informed my thinking.

References

  • Gaines, Atwood D., and Peter J. Whitehouse 2006 Building a Mystery: Alzheimer Disease, Mild Cognitive Impairment and Beyond. Philosophy Psychiatry and Psychology 13(1): 61–74

    Article  Google Scholar 

  • Whitehouse, Peter J. 1997 The International Working Group for Harmonization of Dementia Drug Guidelines: Past, Present, and Future. Alzheimer Disease and Associated Disorders 11(Suppl 3): 2–5

    Google Scholar 

  • Whitehouse, Peter J. 1999 Editorial: Interesting Conflicts and Conflicting Interests. Journal of the American Geriatric Society 47: 1–3

    Google Scholar 

  • Whitehouse, Peter J., Atwood D. Gaines, Heather Lindstrom, and Janice Graham (2005) Dementia in the Anthropological Gaze: Contributions to the Understanding of Dementia. The Lancet Neurology 4: 320–326

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter J. Whitehouse.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whitehouse, P.J. Why I No Longer Consult for Drug Companies. Cult Med Psychiatry 32, 4–10 (2008). https://doi.org/10.1007/s11013-007-9075-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11013-007-9075-x

Keywords

Navigation